December 15, 2025 — cbdMD, Inc. (NYSE American: YCBD) is back on traders’ radars after a sharp, high-volume move that has turned this micro-cap wellness name into one of the most talked-about tickers in the hemp and cannabis-adjacent space this week. The rally is being fueled by a mix of company-specific catalysts (exchange compliance + preliminary FY2025 results) and sector-wide momentum tied to Washington policy headlines. [1]
Below is a full roundup of the latest cbdMD stock news, key SEC details, what management has already guided for fiscal 2025, and where the current YCBD stock forecast stands as of 15.12.2025.
What’s driving cbdMD stock on Dec. 15, 2025?
1) cbdMD regained full NYSE American compliance (and the “.BC” flag is gone)
The most concrete company catalyst in the current cycle: cbdMD announced it has regained full compliance with NYSE American continued listing standards, and the exchange removed the “.BC” (below compliance) indicator effective at the open on December 8, 2025. [2]
In its Form 8‑K, cbdMD disclosed that NYSE Regulation confirmed compliance in a letter dated December 5, 2025, and said the company resolved deficiencies under Sections 1003(a)(i) and (ii)—deficiencies previously referenced in exchange letters dated June 5, 2024 and December 31, 2024. The filing also notes the company remains subject to normal continued listing monitoring going forward. [3]
Why this matters for YCBD stock: micro-cap names can trade with a persistent “survival discount” when delisting risk is front and center. Clearing that overhang often changes the short-term supply/demand balance—especially when combined with thin liquidity and an active retail tape. [4]
2) Preliminary FY2025 results: revenue roughly steady, losses narrowing sharply
On November 21, 2025, cbdMD released preliminary unaudited results for the fourth quarter and fiscal year ended September 30, 2025. The headline numbers the market keeps repeating:
- FY2025 net sales expected $19.1M–$19.3M vs. $19.5M in FY2024
- Q4 FY2025 net sales expected $4.7M–$4.9M vs. $4.6M in Q4 FY2024
- FY2025 net loss expected to improve from $3.7M to $1.9M–$2.1M [5]
Management framed the quarter as evidence that its operating model and cost discipline are taking hold, pointing to sequential and year-over-year revenue growth in Q4 even as many peers posted declines (as characterized in the release). [6]
Just as important: cbdMD said its audited FY2025 financial statements will appear in its Annual Report on Form 10‑K expected to be filed on or before December 29, 2025—a near-term, date-certain catalyst investors are watching. [7]
3) Sector tailwind: cannabis stocks surged on Trump rescheduling headlines
Beyond cbdMD’s own news, the broader cannabis complex has been moving fast.
Reuters reported that cannabis/weed stocks surged after reports that President Donald Trump is expected to push to ease federal marijuana restrictions, including potential movement toward reclassifying marijuana as a Schedule III drug. [8]
That’s not just a vibes story—Schedule III would likely be interpreted as a meaningful policy shift by markets (though not the same as legalization). At the same time, the policy path is not settled: Forbes reported the White House said “no final decisions” had been made on rescheduling. [9]
For cbdMD stock, this matters because YCBD trades in the cannabinoid ecosystem—even though the company markets CBD products and Farm Bill–compliant offerings rather than being a “plant-touching” multistate operator. In practice, when cannabis ETFs and large cannabis names spike, smaller cannabinoid tickers can get swept into the momentum basket. [10]
YCBD stock price action: why traders are calling it “extreme”
Volume is the tell.
StockAnalysis data shows YCBD closed Friday, Dec. 12, 2025 at $1.20, up 90.17%, with reported volume of 302,830,694 shares—a staggering figure for a company this size. The same data set shows pre-market indications on Dec. 15 with YCBD trading higher in early activity. [11]
MarketBeat’s short-interest dashboard (updated 12/15/2025) likewise shows a 12/12 closing price of $1.20, “today’s trading volume” around 301.5M shares, versus an average volume around 16.3M, implying a massive volume shock relative to baseline. [12]
That kind of tape can be driven by a cocktail of:
- headline catalysts (compliance, policy news)
- low float dynamics
- short-term positioning (including short covering)
- retail momentum surges
And it can reverse just as violently as it rises—because liquidity is often thinner than the volume headline suggests once the frenzy cools.
Short interest and float: is a “short squeeze” part of the story?
MarketBeat reports that as of Nov. 28, 2025, cbdMD had 726,585 shares sold short, about 8.32% of the public float, with a short interest ratio of 0.4 days to cover (based on average volume). [13]
A few takeaways for investors trying to interpret the move:
- 8%+ of float short is meaningful, but not automatically “squeeze territory.”
- Days-to-cover under 1 means shorts can theoretically cover quickly under normal conditions—although “normal” disappears in a 300M-share session.
- When the stock trades many multiples of its average daily volume, even modest short interest can add fuel if the price begins to gap. [14]
The compliance fix didn’t happen by magic: capital structure actions that shaped 2025
Series A preferred conversion + 1-for-8 reverse split (May 2025)
cbdMD previously announced an automatic conversion of its Series A preferred into common stock effective May 6, 2025, followed immediately by a one-for-eight reverse stock split, with post-split trading beginning May 7, 2025. The company said outstanding common shares would be consolidated from roughly 71.26M to about 8.91M after these corporate actions. [15]
This matters because reverse splits and conversions can distort “long-term” charts and historical per-share metrics. Anyone analyzing YCBD stock performance should confirm whether their data vendor properly adjusts for the split. [16]
Series B preferred private placement (closed Sept. 30; announced Oct. 1)
On October 1, 2025, cbdMD announced a $1.7M Series B convertible preferred private placement, stating it expected $1.5M net proceeds for working capital and strategic initiatives. The company also disclosed the preferred carries a 10% annual dividend and is convertible at an initial conversion price of $1.00 per share, and that it planned to file a registration statement covering shares issuable upon conversion. [17]
These financing details matter for forecasting and valuation because convertible structures can introduce future dilution depending on conversion, resale registrations, and market conditions.
What does cbdMD actually sell? The business lines investors should understand
cbdMD positions itself as a wellness and hemp-derived products company. Across recent releases, the company highlights:
- a line of CBD products and Farm Bill–compliant Delta-9 offerings
- Paw CBD (pet products)
- Herbal Oasis (hemp-derived THC seltzers)
- ATRx (functional mushroom products) [18]
In 2025, a lot of the brand-expansion narrative has centered on Herbal Oasis:
- Florida distribution expansion via a partnership with Bevtalk Distribution, announced Oct. 9, 2025, aimed at scaling placements across convenience stores, independent retailers, and specialty beverage accounts. [19]
- Tennessee distribution expansion with Best Brands, announced Sep. 16, 2025, following rollouts in multiple Southeast states per that release. [20]
- A product-line move toward higher potency: on Oct. 22, 2025, cbdMD announced new 10mg Herbal Oasis THC seltzer flavors, describing consumer demand for variety and higher potency. [21]
For investors, the key question is whether these distribution wins translate into repeatable sell-through and gross margin durability, rather than one-time channel fill.
The near-term catalyst calendar for YCBD stock
1) FY2025 Form 10‑K deadline: on or before Dec. 29, 2025
cbdMD stated its audited consolidated financial statements for FY2025 will be included in the Form 10‑K expected to be filed on or before Dec. 29, 2025. [22]
That filing will likely be the market’s next major “hard data” checkpoint: cash position, going-concern language (if any), detailed segment discussion, and any updated risk factors.
2) “Mid-December” earnings call language
The preliminary results release referenced an upcoming mid-December earnings call. [23]
Even without an exact date in that release, the message is clear: management expects investor attention on FY2025 details in the immediate term.
3) Cannabis policy headlines
Reuters’ reporting indicates the market is actively trading the probability of policy shifts around marijuana scheduling. That may continue to swing sentiment across the sector, especially in high-beta small caps. [24]
YCBD stock forecast and analyst outlook: limited coverage, but a clear “street” number
One big caveat: traditional Wall Street coverage is thin.
Still, several major market-data platforms converge on roughly the same point:
- MarketBeat shows one analyst with a $2.00 12-month price target (about 66.67% upside from $1.20 in its snapshot). [25]
- StockAnalysis also shows a $2.00 target and labels consensus as Strong Buy, noting price targets were last updated Aug. 20, 2025. [26]
- TradingView’s analyst target display likewise lists $2.00 (max and min at $2.00). [27]
- Fintel aggregates an average one-year price target around $2.04, with a range $2.02–$2.10 and a listed record/projection date pair 2025‑12‑06 → 2026‑12‑06. [28]
How to read this forecast intelligently
When a stock has essentially one tracked analyst, a “consensus” target can look more authoritative than it really is. It’s a data point—not a map of the territory.
In micro-caps, price targets often function less like finely tuned valuation models and more like directional thesis markers that can lag fast-changing liquidity and capital structure realities.
The risk section that matters for cbdMD stock right now
Even with the excitement, there are several reasons YCBD remains a high-risk equity:
- Volatility and liquidity risk: 300M-share days can cut both ways; sharp reversals are common in micro-caps after momentum fades. [29]
- Regulatory and policy uncertainty: the entire cannabinoid category is sensitive to federal and state shifts, and the current cannabis scheduling headlines are explicitly described as not final by some reporting. [30]
- Dilution/structure complexity: convertible preferred financing and registration rights can introduce supply over time, depending on conversion and resale behavior. [31]
- Financial reporting catalyst risk: the upcoming 10‑K is a major event; audited numbers can confirm guidance—or force revisions. [32]
Bottom line: cbdMD stock is moving on a rare alignment of catalysts
As of Dec. 15, 2025, cbdMD (YCBD) is in the middle of a classic small-cap storm:
- A real corporate milestone (NYSE American compliance regained) [33]
- A fundamental narrative that’s at least directionally improving (losses projected to narrow in FY2025) [34]
- A macro tailwind that is whipping the whole sector (possible marijuana rescheduling headlines) [35]
- Plus the mechanical accelerants (extreme volume + meaningful short interest) [36]
For investors, the next “truth serum” is likely the audited FY2025 Form 10‑K (due on or before Dec. 29, 2025) and whatever guidance or strategic color management provides around distribution traction, margins, and cash runway. [37]
References
1. www.prnewswire.com, 2. www.prnewswire.com, 3. www.sec.gov, 4. www.prnewswire.com, 5. www.prnewswire.com, 6. www.prnewswire.com, 7. www.prnewswire.com, 8. www.reuters.com, 9. www.forbes.com, 10. www.reuters.com, 11. stockanalysis.com, 12. www.marketbeat.com, 13. www.marketbeat.com, 14. www.marketbeat.com, 15. www.newsfilecorp.com, 16. www.newsfilecorp.com, 17. www.newsfilecorp.com, 18. www.prnewswire.com, 19. www.prnewswire.com, 20. www.newsfilecorp.com, 21. www.stocktitan.net, 22. www.prnewswire.com, 23. www.prnewswire.com, 24. www.reuters.com, 25. www.marketbeat.com, 26. stockanalysis.com, 27. www.tradingview.com, 28. fintel.io, 29. stockanalysis.com, 30. www.reuters.com, 31. www.newsfilecorp.com, 32. www.prnewswire.com, 33. www.prnewswire.com, 34. www.prnewswire.com, 35. www.reuters.com, 36. stockanalysis.com, 37. www.prnewswire.com
